PharmAsia News
August 14, 2013
Executive SummaryAnother China agency has begun an investigation into the nation's bribery scandals, this time the agency responsible for market supervision, a move beyond an emphasis on price-fixing in drugs and baby formula sectors.
Another China agency has begun an investigation into the nation's bribery scandals, this time the agency responsible for market supervision, a move beyond an emphasis on price-fixing in drugs and baby formula sectors. Meanwhile, Novartis said it would launch its own internal probe of bribery allegations concerning its employees in China, a case complicated by a whistleblower's effort to get out of a company contract. The State Administration for Industry and Commerce, an antitrust regulator, said its intent is to eliminate commercial bribery. The SAIC also said it would punish severely any cases it finds of bribery in the nation's bidding process for drugs and medical services.
Executive SummaryAnother China agency has begun an investigation into the nation's bribery scandals, this time the agency responsible for market supervision, a move beyond an emphasis on price-fixing in drugs and baby formula sectors.
Another China agency has begun an investigation into the nation's bribery scandals, this time the agency responsible for market supervision, a move beyond an emphasis on price-fixing in drugs and baby formula sectors. Meanwhile, Novartis said it would launch its own internal probe of bribery allegations concerning its employees in China, a case complicated by a whistleblower's effort to get out of a company contract. The State Administration for Industry and Commerce, an antitrust regulator, said its intent is to eliminate commercial bribery. The SAIC also said it would punish severely any cases it finds of bribery in the nation's bidding process for drugs and medical services.